AN2 Therapeutics (ANTX) Non-Current Assets (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Non-Current Assets for 5 consecutive years, with $2.0 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Non-Current Assets fell 65.44% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $13.5 million (down 27.44% YoY), while the FY2025 annual figure was $2.0 million, down 65.44% from the prior year.
• Non-Current Assets slipped to $2.0 million in Q4 2025 per ANTX's latest filing, from $3.2 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $28.2 million in Q4 2023 and bottomed at $720000.0 in Q1 2022.
• Historically, Non-Current Assets has averaged $6.9 million across 5 years, with a median of $3.6 million in 2022.
• Annual changes were most pronounced in 2023 — Non-Current Assets jumped 910.29% — and 2024, when it sank 79.37%.
• AN2 Therapeutics' Non-Current Assets stood at $5.2 million in 2021, then fell by 24.4% to $3.9 million in 2022, then soared by 616.86% to $28.2 million in 2023, then tumbled by 79.37% to $5.8 million in 2024, then tumbled by 65.44% to $2.0 million in 2025.
• Business Quant data shows ANTX's Non-Current Assets at $2.0 million in Q4 2025, $3.2 million in Q3 2025, and $8.3 million in Q2 2025.